AMAG Pharmaceuticals Inc

Type: Company
Name: AMAG Pharmaceuticals Inc
First reported Apr 16 2014 - Updated Apr 17 2014 - 2 reports

AMAG Pharmaceuticals, Inc. Announces Appointment Of To Its Board Of Directors And The Transition Of Chairman Role To

(GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, ... [Published BioSpace - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Broadfin Capital Initiates New Positions In Corium International Inc (CORI), AMAG Pharmaceuticals Inc. (AMAG) and La Jolla Pharmaceutical Company (LJPC)

In three recent filings,   Kevin Kotler’s Broadfin Capital has revealed adding three companies:  Corium International Inc (NASDAQ : CORI ) , AMAG Pharmaceuticals Inc. (NASDAQ : AMAG ) and La Jolla Pharmaceutical Company (NASDAQ : LJPC )  to its equity ... [Published InsiderMonkey.com - Apr 17 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

AMAG Pharmaceuticals: The Losing Streak Continues (AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) traded at a new 52-week low today of $16.75. Approximately 670,000 shares have changed hands today, as compared to an average 30-day volume of 531,000 shares. ... [Published Individual.com - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Attention Investors who purchased NASDAQ:AMAG shares: Investigation announced

The Shareholders Foundation announces that the investigation on behalf of current long-term investors in shares of AMAG Pharmaceuticals , Inc. (NASDAQ:AMAG) continues concerning potential breaches of fiduciary duties that caused damages to the company ... [Published Empowered News - Apr 14 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 1 reports

AMAG Pharmaceuticals Shares Down 25.1% Since SmarTrend's Sell Call (AMAG)

SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 25.10% as of today's recent price of $18.1 ... [Published Individual.com - Apr 07 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

AMAG Pharmaceuticals: New 52-Week Low Set Today (AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) traded today at a new 52-week low of $17.54. Approximately 227,000 shares have changed hands today, as compared to an average 30-day volume of 586,000 shares. ... [Published Individual.com - Apr 07 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

AMAG Pharmaceuticals Sets New 52-Week Low at $18.43 (AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) reached a new 52-week low on Thursday , AnalystRatingsNetwork.com reports. The stock traded as low as $18.43 and last traded at $18.63, with a volume of 152,751 shares changing hands. The stock had previously closed ... [Published American Banking News - Apr 03 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Shares of AMAG Pharmaceuticals Have Fallen Below Previous 52-Week Low

AMAG Pharmaceuticals (NASDAQ:AMAG) traded today at a new 52-week low of $18.43. Approximately 184,000 shares have changed hands today, as compared to an average 30-day volume of 605,000 shares. ... [Published Individual.com - Apr 03 2014]
First reported Apr 01 2014 - Updated Apr 02 2014 - 2 reports

AMAG Pharmaceuticals, Inc. To Present At The Healthcare Conference

(GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. ET in New York. The ... [Published BioSpace - Apr 02 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 2 reports

AMAG Pharmaceuticals (AMAG) Trading Near $19.82 Resistance Level

The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on AMAG Pharmaceuticals (AMAG) that includes 13.95% downside protection.Sell one contract of the Aug. ... [Published Market Intelligence Center - Apr 01 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

AMAG Pharmaceuticals Has Returned 13.7% Since SmarTrend Recommendation (AMAG)

SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 13.72% as of today's recent price of $2 ... [Published Individual.com - Mar 24 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

AMAG Pharmaceuticals (AMAG) Trading Near $21.03 Support Level

The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on AMAG Pharmaceuticals (http://www.marketintelligencecenter.com/symbol/AMAG"AMAG) that includes 14.81% ... [Published Individual.com - Mar 21 2014]

Quotes

...flammation, erosive ulceration and significant pain," stated Jeffrey B Davis, President and CEO of Access PharmaceuticalsAccess Pharmaceuticals Inc. "The results of this study, like others previously announced by Access, add to the growing body of clinical evidence of the significant benefits offered by MuGard ® to patients suffering with a variety of conditions of the oral cavity."
"The hiring of Scott as Vice President, Marketing and Sales and Steve as Senior Director, Scientific Affairs is an important milestone as we continue to develop our pipeline of renal products and prepare for the commercial launch of Rayaldee to treat CKD patients" said Phillip Frost , M D , Chairman and CEO of Opko. "We are pleased to welcome Scott and Steve."
"Leveraging upon our success with MuGard®, Access is actively working on a number of follow-on products that focus on applications of our base product in other mucosal tissue, such as the recently discussed ProctiGard™ for the treatment of radiation proctitis, and now LexaGard™ which incorporates an active pharmaceutical agent" stated Jeffrey B Davis
...us to identify patients most likely to benefit from MM-398 treatment," said Jonathan Fitzgerald, Ph D , Senior Director of Discovery at Merrimack. "Though our initial data are from a small sample of a diverse patient population, we are encouraged to see that almost all of the tumor lesions that shrank after MM-398 treatment were associated with higher levels of ferumoxytol, as seen on the MRI."

More Content

All (79) | News (57) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (18)
sort by: Date | Relevance
AMAG Pharmaceuticals, Inc. Announces Appointmen... [Published BioSpace - Apr 17 2014]
Broadfin Capital Initiates New Positions In Cor... [Published InsiderMonkey.com - Apr 17 2014]
AMAG Pharmaceuticals announces transition of ch... [Published Reuters UK - Apr 16 2014]
AMAG Pharmaceuticals Announces Appointment of J... [Published GlobeNewswire: Acquisitions News - Apr 16 2014]
AMAG PHARMACEUTICALS : Change in Directors or P... [Published 4 Traders - Apr 16 2014]
AMAG Pharmaceuticals: The Losing Streak Continu... [Published Individual.com - Apr 15 2014]
Positive Results Of MuGard Study In Erosive Ora... [Published Yahoo! Finance - Apr 15 2014]
AMAG Pharmaceuticals Has Returned 28.6% Since S... [Published Comtex SmarTrend - Apr 14 2014]
AMAG Pharmaceuticals Has Returned 28.6% Since S... [Published Individual.com - Apr 14 2014]
Attention Investors who purchased NASDAQ:AMAG s... [Published Empowered News - Apr 14 2014]
OPKO HEALTH : Updates on Key Executive Appointm... [Published 4 Traders - Apr 13 2014]
Mealey's Securities/D&O Liability - Judge Denie... [Published Mealey - Apr 11 2014]
AMAG PHARMACEUTICALS : Regulation FD Disclosure... [Published 4 Traders - Apr 09 2014]
OPKO Health announces management changes [Published Individual.com - Apr 09 2014]
Access Pharmaceuticals Provides Update On Devel... [Published Benzinga.com - Apr 08 2014]
Merrimack Announces Preliminary Data From Pilot... [Published Benzinga.com - Apr 08 2014]
Opko Health Reports Key Executive Appointments ... [Published PredictWallStreet - Apr 08 2014]
OPKO HEALTH : Names Key Executive Appointments ... [Published 4 Traders - Apr 08 2014]
OPKO HEALTH : Reports Key Executive Appointment... [Published 4 Traders - Apr 08 2014]
AMAG Pharmaceuticals: New 52-Week Low Set Today... [Published Individual.com - Apr 07 2014]
AMAG Pharmaceuticals Shares Down 25.1% Since Sm... [Published Individual.com - Apr 07 2014]
OPKO Health Appoints Scott Toner and Steve Stru... [Published Citybizlist - Apr 04 2014]
AMAG Pharmaceuticals Sets New 52-Week Low at $1... [Published American Banking News - Apr 03 2014]
Shares of AMAG Pharmaceuticals Have Fallen Belo... [Published Individual.com - Apr 03 2014]
OPKO Health Announces Key Executive Appointment... [Published Investor's Business Daily - Apr 03 2014]
Access Pharmaceuticals Cobraxane™ Offers Enhanc... [Published HispanicBusiness.com - Apr 03 2014]
AMAG Pharmaceuticals, Inc. To Present At The He... [Published BioSpace - Apr 02 2014]
AMAG Pharmaceuticals, Inc. to Present at the Ne... [Published GlobeNewswire: Advertising News - Apr 01 2014]
AMAG Pharmaceuticals, Inc. to Present at the Ne... [Published OSIX News - Apr 01 2014]
AMAG Pharmaceuticals (AMAG) Trading Near $19.82... [Published Market Intelligence Center - Apr 01 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Pharmaceutical IT chief melds five cloud securi... [Published Computerworld - Security RSS feed - Jan 29 2014]
Having migrated his company from on-site servers and applications to a cloud-based software-as-a-service, Nathan McBride, vice president of information technology at AMAG Pharmaceuticals, is now working to influence security by getting five cloud security ...
Frontrunning: January 23 [Published Zero Hedge - Jan 23 2014]
Gross Told El-Erian ‘Hell No’ Seeking to Stop Departure ( BBG ) How Caterpillar got bulldozed in China ( Reuters ) Davos Bankers Struggle to Convince Elite That Markets Are Safer ( BBG ) Lucrative Role as Middleman Puts Amazon in Tough Spot ( WSJ ) Arctic ...
FDA rejects wider use of Amag anemia drug; shar... [Published Yahoo! Health News - Jan 22 2014]
(Reuters) - Amag Pharmaceuticals Inc said the U.S. Food and Drug Administration rejected its application for wider use of its iron deficiency drug due to safety concerns and asked for more trial data. The FDA asked Amag to provide additional safe... ...
FDA rejects wider use of Amag's anemia drug [Published Yahoo! Health News - Jan 22 2014]
(Reuters) - Amag Pharmaceuticals Inc said the U.S. Food and Drug Administration rejected its application for a wider use of its iron deficiency drug, sending its shares down 18 percent in premarket trade. The regulator said the company had not pr... ...
1

Press Releases

sort by: Date | Relevance
AMAG Pharmaceuticals Announces Appointment of J... [Published GlobeNewswire: Acquisitions News - Apr 16 2014]
AMAG Pharmaceuticals, Inc. to Present at the Ne... [Published GlobeNewswire: Advertising News - Apr 01 2014]
Stock Price Updates, Appointment, and Financial... [Published Financial Services - Mar 06 2014]
AMAG Pharmaceuticals, Inc. to Participate in th... [Published GlobeNewswire: Advertising News - Feb 27 2014]
Study Shows MuGard(R) is More Effective Than Sh... [Published GlobeNewswire: Advertising News - Feb 18 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.